Assessment of pleiotropic and proteinuria reducing effect of irbesartan in chronic kidney disease patients

Assessment of pleiotropic and proteinuria reducing effect of irbesartan in chronic kidney disease patients - Pleiotropic effect of irbesartan in chronic kidney disease patients

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002423

Enrollment

Registered

2009-09-07

Start date

2009-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic kidney disease stage 1-4

Interventions

irbesartan

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Renal dysfunction: CKD stage 1-4 2) Expected survival time is more than 6 months 3) Aged 20 years over 4) Fully informed consent was obtained

Exclusion criteria

Exclusion criteria: 1) Patients who has past history of adverse effect of taking another ARB 2) Pregnancy 3) Patients who has serious liver disease and coronary heart disease or nephrotic syndrome 4) Judged inappropriate for this study by the physicians

Design outcomes

Primary

Measure	Time frame
The primary outcome is proteinuria reducing effect at four, twelve and twenty-four months after administration of the ARB case compared with at baseline.	—

Secondary

Measure	Time frame
The secondary outcome is the impact of irbesartan on adiponectin, leptin, IGF-1, hsCRP, IL-6, IL-10. TNF, at four, twelve and twenty-four months after administration of the ARB case compared with at baseline.	—

Countries

Japan

Contacts

Public ContactHirokazu Honda

Showa University School of Medicine Division of Nephrology Department of Medicine

hondah@med.showa-u.ac.jp03-3784-8533

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026